Manipal Health Enterprises Limited IPO Overview
Manipal Health Enterprises Limited is one of India’s largest multi-specialty healthcare providers, operating hospitals, clinics, and diagnostic centres across the country. It offers advanced treatments in organ transplants, oncology, cardiology, neurosciences, orthopaedics, renal sciences, and preventive care. As of March 31, 2026, the company operated 49 hospitals with 13,037 licensed beds across 14 states and union territories. It is the largest private hospital network in India by bed capacity and the second-largest by hospital count. Its growth has been supported by acquisitions such as Columbia Asia, AMRI Hospitals, Medica Synergie, and Sahyadri Group. The network employed over 11,000 doctors, 11,000 nurses, and 6,300 paramedics.
Manipal Health Enterprises is backed by Temasek, Singapore’s state investment company, and is set to launch India’s largest healthcare IPO by issue size on July 29, 2026, seeking to raise ₹9,275.22 crore at a price band of ₹560–₹590 per share. The company will be valued at approximately ₹77,607 crore at the upper end of the price band. The IPO opens on July 29, 2026 and closes on July 31, 2026, with listing expected on August 5, 2026 on both BSE and NSE.
IPO Detailed Information
Issue Details
| Parameter | Details |
| IPO Type | Book Built – Mainboard |
| Listing Exchange | BSE & NSE |
| Anchor Investor Date | 28 July 2026 |
| IPO Open Date | 29 July 2026 |
| IPO Close Date | 31 July 2026 |
| Allotment Date | 3 August 2026 (Expected) |
| Refund Initiation | 4 August 2026 |
| Credit to Demat | 4 August 2026 |
| Listing Date | 5 August 2026 (Tentative) |
| Price Band | ₹560 – ₹590 per share |
| Face Value | ₹2 per share |
| Lot Size | 25 shares |
| Minimum Investment (Retail) | ₹14,750 (approx) |
| Issue Size | ₹9,275.22 crore |
| Fresh Issue | 13,55,93,220 shares (₹8,000 crore) |
| Offer For Sale (OFS) | 2,16,13,834 shares (₹1,275.22 crore) |
Note: The IPO comprises a fresh issue of ₹7,998.43 crore and an Offer for Sale of ₹1,275.22 crore by existing shareholders. The company will receive fresh issue proceeds while OFS proceeds go to the selling shareholders.
Issue Break-up
| Category | Allocation |
| Qualified Institutional Buyers (QIB) | ~50% |
| Non-Institutional Investors (NII/HNI) | ~15% |
| Retail Individual Investors (RII) | ~35% |
OFS / Selling Shareholders
Promoters Imperius Healthcare Investments and Manipal Education and Medical Group India, along with investors TPG SG Magazine, Seventy Second Investment Company, Ammar Sdn Bhd, Novo Holdings Invest Asia, and Phoenix Bear Investments will sell shares through the OFS route.
Promoters Ranjan Ramdas Pai and affiliated MEMG entities hold 81.42% pre-IPO stake, and Temasek is among the key institutional investors.
Objects of the Issue (Fund Utilization)
The net proceeds from the fresh issue will be utilised for the following purposes: repayment/prepayment, in full or in part, of certain outstanding borrowings availed by its material subsidiary Manipal Hospitals Private Limited — ₹5,552.76 crore; acquisition of minority stake in its step-down subsidiary Sahyadri Hospitals Private Limited — ₹574 crore; and general corporate purposes.
- Repayment / prepayment of subsidiary borrowings (Manipal Hospitals Pvt. Ltd.) — ₹5,552.76 crore
- Acquisition of minority stake in Sahyadri Hospitals Pvt. Ltd. — ₹574 crore
- General corporate purposes — remaining proceeds
Note: OFS proceeds will go entirely to the selling shareholders and not to the company.
Lead Managers & Registrar
- Book Running Lead Managers: Kotak Mahindra Capital Company Ltd., Axis Capital Ltd., Goldman Sachs (India) Securities Pvt. Ltd., Jefferies India Pvt. Ltd., J.P. Morgan India Pvt. Ltd., UBS Securities India Pvt. Ltd., and DBS Bank India Ltd.
- Registrar to the Issue: Kfin Technologies Ltd.
Promoters & Management
The promoters are Dr. Ranjan Ramdas Pai, along with Manipal Global Health Services, MEMG International Ltd., Kangto Investments Pte. Ltd., Imperius Healthcare Investments Pte. Ltd., and Kabru Investments Pte. Ltd.
Manipal Health Enterprises Limited was originally incorporated in February 2010 as Manipal Health Enterprises Private Limited. It was subsequently converted into a public limited company and renamed Manipal Health Enterprises Limited in December 2025.
Company Details
Manipal Health Enterprises is one of India’s largest multi-specialty healthcare providers. The company delivers integrated healthcare services through hospitals, outpatient clinics, diagnostic centres, and specialised medical facilities spread across the country. Its growth has been supported by a series of strategic acquisitions including Columbia Asia, AMRI Hospitals, Medica Synergie, and the Sahyadri Group.
Specialties & Services:
- Oncology, Cardiology, Neurosciences
- Organ Transplants (Kidney, Liver, Heart)
- Orthopaedics, Renal Sciences
- Preventive & Outpatient Care
- Diagnostics & Imaging
Key Capabilities:
- India’s largest multispecialty hospital network by bed capacity, with leadership positions in three major metros and one of India’s most recognisable healthcare brands. Proven M&A and integration playbook — including acquisition of Columbia Asia (11 hospitals, ₹2,100 crore) and Vikram Hospital in 2021.
- As of March 31, 2026, 41 of its hospitals were accredited by the National Accreditation Board for Hospitals and Healthcare Providers (NABH), while 24 hospital laboratories were accredited by the NABL.
Hospital Network (as of March 31, 2026):
- 49 Hospitals
- 13,037 Licensed Beds
- 14 States and Union Territories
- 11,000+ Doctors | 11,000+ Nurses | 6,300+ Paramedics
Financial Snapshot
| Period | Revenue from Operations (₹ Cr) | Total Income (₹ Cr) | PAT (₹ Cr) | EBITDA (₹ Cr) |
| FY24 | ₹6,171.63 | ₹6,265.17 | ₹533.20 | ₹1,776.60 |
| FY25 | ₹8,242.25 | ₹8,362.79 | ₹1,081.67 | ₹2,455.03 |
| FY26 | ₹10,335.75 | ₹10,520.51 | ₹916.52 | ₹2,795.94 |
Key Financial Metrics
- Revenue from operations grew from ₹6,171.63 crore in FY24 to ₹10,335.75 crore in FY26 — a CAGR of 29.41% over two years.
- EBITDA margin remained healthy at approximately 27.4% in FY25, driven by high hospital occupancy of 67.1% and an Average Revenue Per Occupied Bed (ARPOB) of ₹63,312 per day.
- PAT margin stood at 8.64% (FY24), 13.12% (FY25), and 8.87% (FY26). RoCE was 27.74% (FY24), 26.98% (FY25), and 21.88% (FY26). Average EPS (basic) over three years: ₹7.82. Average RoNW: 13.80%.
- Total borrowings rose sharply from ₹4,766.83 crore in FY25 to ₹10,553.43 crore in FY26, largely due to recent acquisitions including the Sahyadri Group.
- Post-issue P/E stands at approximately 105x FY26 proforma earnings — a significant premium to all listed hospital peers including Apollo Hospitals.
Company Strengths
- India’s largest pan-India multispecialty hospital network by bed capacity, and the second-largest private hospital chain by number of hospitals — a dominant market position in a highly fragmented sector.
- Proven acquisition and integration track record — successfully integrated hospital groups of varying sizes including Columbia Asia, Vikram Hospital, AMRI, Medica Synergie, and the Sahyadri Group, while improving their margins post-acquisition.
- Strong revenue growth with ARPOB of ₹63,312 per day in FY25, improving to ₹66,144 in FY26, reflecting a high-quality case mix and improving payer profile.
- Strong institutional backing from Temasek, one of Singapore’s most respected sovereign investment funds, lending global credibility and governance oversight.
- 41 of its 49 hospitals accredited by NABH and 24 laboratories accredited by NABL — reflecting high clinical quality standards across the network.
- Fresh issue proceeds being used to reduce debt significantly — expected to lower interest costs and support future margin improvement.
Key Risks & Challenges
- Revenue concentration in Karnataka — the state accounted for 46.40% of total revenue from operations in FY26, making it the single largest geographic exposure despite some reduction from 59.98% in FY24.
- Aggressive valuation at approximately 105x post-issue P/E on proforma FY26 earnings — a steep premium to all listed hospital peers including Apollo Hospitals, leaving limited margin of safety.
- Total borrowings more than doubled from ₹4,766.83 crore in FY25 to ₹10,553.43 crore in FY26, driven by acquisition funding. Net Debt to Adjusted EBITDA spiked to 3.74x in FY26 from 2.00x in FY25.
- PAT declined in FY26 to ₹916.52 crore despite significantly higher revenue of ₹10,520.51 crore — attributed to higher employee costs, finance charges, depreciation, and expansion-related expenses.
- High dependence on key medical talent — loss of senior doctors or specialists can directly impact revenue and patient volumes at individual hospitals.
- All three recently listed hospital sector IPOs listed at losses — indicating weak secondary market sentiment for healthcare listings at the time of this offering.
Disclaimer:
This document is for informational purposes only and should not be considered as investment advice. Investors should read the Red Herring Prospectus (RHP) carefully and consult a financial advisor before investing in any IPO. Market investments are subject to risk.
